An advertisement for BergaMet products, which we published on this website, should not have been published.
In the advertisement we unlawfully made claims that BergaMet could have benefits in relation to weight loss, cardiovascular disease, fatty liver, cholesterol levels, insulin resistance, diabetes, high blood pressure, heart disease, heart attack, stroke and many other serious health concerns. We also implied that the claims about the products and/or its ingredients were adequately supported by clinical research and were endorsed by healthcare professionals, that the products was “100%” natural, and that it was more effective or superior to other bergamot extract products and offered the highest level of purity and the largest dosage.
A complaint about the advertisement was recently upheld by the Complaints Resolution Panel. The evidence we provided to support the claims about product benefits, and the comparative claims, was not sufficient to support those claims. The Panel found that the claims were misleading and unverified, or otherwise unlawful and breached the Therapeutic Goods Advertising Code and Therapeutic Goods Act.
The Panel therefore requested that DOJS Holdings Pty Ltd, trading as Nathealth Solutions, publish this retractions.
The full text of the Pane’ls determination can be found at www.tgacrp.com.au/complaints (reference 2016/12/001)